MedPath

Ipilimumab

Generic Name
Ipilimumab
Brand Names
Yervoy
Drug Type
Biotech
Chemical Formula
-
CAS Number
477202-00-9
Unique Ingredient Identifier
6T8C155666
Background

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication

Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer

- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab

Associated Conditions
Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
Associated Therapies
First Line Chemotherapy

The Sagittarius Trial

First Posted Date
2024-07-08
Last Posted Date
2024-11-11
Lead Sponsor
IFOM ETS - The AIRC Institute of Molecular Oncology
Target Recruit Count
700
Registration Number
NCT06490536
Locations
🇮🇹

Istituto Clinico Humanitas, Rozzano, Milano, Italy

🇮🇹

Istituto di Candiolo, Candiolo, Torino, Italy

🇮🇹

Azienda Sanitaria Locale di Biella, Biella, Italy

and more 11 locations

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Phase 2
Recruiting
Conditions
Colorectal Cancer
Gastroesophageal Cancer
Interventions
First Posted Date
2024-05-13
Last Posted Date
2025-01-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
65
Registration Number
NCT06410534
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer

Phase 1
Not yet recruiting
Conditions
Very High Risk Prostate Carcinoma
Interventions
Radiation: [177Lu]Lu-PSMA-617
Drug: Ipilimumab
First Posted Date
2024-04-29
Last Posted Date
2024-04-29
Lead Sponsor
University Hospital, Essen
Target Recruit Count
58
Registration Number
NCT06388369
Locations
🇩🇪

University Hospital Essen, Clinic of Urology, Essen, Germany

CARE1 Pragmatic Clinical Trial

Phase 3
Recruiting
Conditions
Metastatic Kidney Cancer
Metastatic Kidney Carcinoma
Interventions
First Posted Date
2024-04-15
Last Posted Date
2024-04-19
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
1250
Registration Number
NCT06364631
Locations
🇫🇷

Gustave Roussy, Villejuif, France

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Phase 2
Not yet recruiting
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2024-04-15
Last Posted Date
2024-10-18
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
24
Registration Number
NCT06364917
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Phase 2
Recruiting
Conditions
Melanoma
Interventions
First Posted Date
2024-04-15
Last Posted Date
2024-12-11
Lead Sponsor
University of Utah
Target Recruit Count
25
Registration Number
NCT06365619
Locations
🇺🇸

Huntsman Cancer Institute, Salt Lake City, Utah, United States

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Phase 1
Recruiting
Conditions
Pleural Mesothelioma
Renal Cell Cancer
Kidney Cancer
Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
ALK Genomic Tumor Aberrations
Melanoma
Advanced Cancer
Metastasis
Advanced Solid Tumor
Skin Cancer
Interventions
First Posted Date
2024-04-12
Last Posted Date
2024-11-25
Lead Sponsor
7 Hills Pharma, LLC
Target Recruit Count
126
Registration Number
NCT06362369
Locations
🇺🇸

Florida Cancer Specialists, Lake Mary, Florida, United States

🇺🇸

Dartmouth Hitchcock, Lebanon, New Hampshire, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

Phase 2
Recruiting
Conditions
Metastatic Breast Cancer
Interventions
First Posted Date
2024-04-02
Last Posted Date
2024-06-14
Lead Sponsor
The Netherlands Cancer Institute
Target Recruit Count
60
Registration Number
NCT06342037
Locations
🇳🇱

Antoni van Leeuwenhoek, Amsterdam, Noord-Holland, Netherlands

Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Phase 1
Not yet recruiting
Conditions
Anatomic Stage I Breast Cancer AJCC V8
Anatomic Stage IA Breast Cancer AJCC V8
Anatomic Stage IB Breast Cancer AJCC V8
Anatomic Stage II Breast Cancer AJCC V8
Anatomic Stage IIB Breast Cancer AJCC V8
Anatomic Stage IIA Breast Cancer AJCC V8
Metastatic Triple-Negative Breast Carcinoma
Prognostic Stage IA Breast Cancer AJCC V8
Prognostic Stage IB Breast Cancer AJCC V8
Anatomic Stage III Breast Cancer AJCC V8
Interventions
First Posted Date
2024-03-21
Last Posted Date
2024-11-05
Lead Sponsor
Emory University
Target Recruit Count
18
Registration Number
NCT06324240
Locations
🇺🇸

Grady Health System, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

and more 1 locations

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Phase 2
Recruiting
Conditions
Melanoma Stage III
Advanced Melanoma
Melanoma
Melanoma Stage IV
Interventions
First Posted Date
2024-03-06
Last Posted Date
2024-12-17
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
90
Registration Number
NCT06295159
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath